These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 26295044)

  • 41. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.
    Członkowska A; Kurkowska-Jastrzebska I; Członkowski A; Peter D; Stefano GB
    Med Sci Monit; 2002 Aug; 8(8):RA165-77. PubMed ID: 12165754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.
    Qian L; Flood PM; Hong JS
    J Neural Transm (Vienna); 2010 Aug; 117(8):971-9. PubMed ID: 20571837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Hirsch EC; Hunot S
    Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased Levels of Pro-Inflammatory and Anti-Inflammatory Cellular Responses in Parkinson's Disease Patients: Search for a Disease Indicator.
    Yang L; Guo C; Zhu J; Feng Y; Chen W; Feng Z; Wang D; Sun S; Lin W; Wang Y
    Med Sci Monit; 2017 Jun; 23():2972-2978. PubMed ID: 28624842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parkinson's disease and enhanced inflammatory response.
    Stojkovska I; Wagner BM; Morrison BE
    Exp Biol Med (Maywood); 2015 Nov; 240(11):1387-95. PubMed ID: 25769314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
    Teismann P; Schulz JB
    Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glial cell response: A pathogenic factor in Parkinson's disease.
    Wu DC; Tieu K; Cohen O; Choi DK; Vila M; Jackson-Lewis V; Teismann P; Przedborski S
    J Neurovirol; 2002 Dec; 8(6):551-8. PubMed ID: 12476349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. M1 and M2 immune activation in Parkinson's Disease: Foe and ally?
    Moehle MS; West AB
    Neuroscience; 2015 Aug; 302():59-73. PubMed ID: 25463515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease.
    Kustrimovic N; Marino F; Cosentino M
    Curr Med Chem; 2019; 26(20):3719-3753. PubMed ID: 30306855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of T cells in the pathogenesis of Parkinson's disease.
    Chen Z; Chen S; Liu J
    Prog Neurobiol; 2018 Oct; 169():1-23. PubMed ID: 30114440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Inflammation and Parkinson's disease].
    Barcia González C; Herrero Ezquerro MT
    Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
    Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
    Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
    Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
    Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation.
    Trudler D; Nash Y; Frenkel D
    J Neural Transm (Vienna); 2015 Oct; 122(10):1409-19. PubMed ID: 25894287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.
    Lu J; Xu Y; Quan Z; Chen Z; Sun Z; Qing H
    Neuroscience; 2017 Dec; 365():70-82. PubMed ID: 28964753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.